Mesorlagine induced interstitial nephritis

P J Thuluvath, M Ninkovic, J Calam, M Anderson

Abstract
5-Aminosalicylic acid (5-ASA) has structural similarities to both phenacetin and aspirin, which are known to cause 'analgesic nephropathy'. Because of the increasing use of 5-ASA, this paper draws attention to two cases of severe interstitial nephritis resulting from 5-ASA and emphasises the importance of monitoring renal functions of patients with inflammatory bowel disease who are receiving 5-ASA preparations.

(Gut 1994; 35: 1493-1496)

Sulphasalazine was until recently the preferred drug for many patients with inflammatory bowel disease. Because of the considerable adverse effects, probably related to the sulfapyridine component, the recent trend has been to use the active moiety of sulphasalazine, 5-aminosalicylic acid (5-ASA). 5-ASA is commercially available in the United Kingdom and the United States as mesalazine (Pentasa, 250 mg microgranules coated with ethyl cellulose as a slow release preparation, Asacol, 400 mg tablets coated with an acrylic based resin, which is released in the gut when pH is above 7) and olsalazine (Dipentum 250 mg tablets where two molecules of 5-ASA are linked by an azo bond). We report two cases of severe interstitial nephritis induced by Asacol to emphasise the importance of monitoring renal functions of patients who take 5-ASA preparations.

Case reports

CASE 1
A 28 year old man with no previous medical problems was seen in the gastroenterology clinic in April 1988 with bloody diarrhoea and lower abdominal pain. Clinical examination, blood counts, urine analysis, urea, and electrolytes were normal. Flexible sigmoidoscopy showed features suggestive of mild ulcerative colitis, which was confirmed on rectal biopsy. The symptoms settled down with mesalazine (Asacol) 400 mg three times daily and hydrocortisone (Colifoam) enema. In June 1990 he had a flare up of colitis and barium enema showed mild total colitis. Asacol was increased to 800 mg three times daily and prednisolone 40 mg was started. Although he improved initially, when prednisolone was reduced the diarrhoea worsened and he was admitted for intravenous hydrocortisone. During that admission he was found to have increased urea (7 mmol) and creatinine (394 mmol/l) values. Creatinine clearance was 45 ml/minute and urine protein was 2.9 g/24 hours. Asacol was stopped. Renal ultrasound, urine microscopy, calcium anti-glomerular basement membrane antibodies (GBM), anti-nuclear antibodies (ANA), rheumatoid factor, DNA binding, anti-cardiolipin antibody, cryoglobulins, immunoglobulins, and complements were either normal or negative. His creatinine clearance remained at 49 ml/min at three months after treatment with the drug had finished and a renal biopsy performed at that stage showed severe interstitial nephritis (Figure). A trial of prednisolone 60 mg daily was given without any improvement in renal functions. At the time of reporting he had developed hypertension, which required medical treatment. The ulcerative colitis has remained quiescent without any treatment.

CASE 2
A 24 year old man without any previous medical history was seen in the gastroenterology clinic in February 1988 with a short history of bloody diarrhoea. Sigmoidoscopy showed diffuse colitis and biopsy showed ulcerative colitis. A white cell scan showed pancolitis. His renal functions showed normal electrolyte, urea (3.6 mmol), and creatinine (88 umol/l) values. He was treated with Asacol 800 mg three times daily and hydrocortisone enemas with symptomatic recovery. He was given maintenance treatment with Asacol 800 mg three times daily. He had a relapse of colitis a few months later, which required oral prednisolone. When prednisolone was withdrawn in December 1989 he had a further relapse, which was again treated with corticosteroids. His creatinine rose through the normal range and was abnormal at 153 umol/l in August 1989 and by February 1991 had reached concentrations over 300 umol/l when Asacol was withdrawn. He was given maintenance treatment with prednisolone 6 mg daily. His renal functions remained unchanged and in April 1991 he was admitted for renal biopsy. Clinical examination, blood counts, electrolytes, liver function tests, calcium and C reactive protein were normal. Anti-neutrophil cytoplasmic antibodies, anti-GBM, ANA, rheumatoid factor, DNA binding, anti-cardiolipin antibody, cryoglobulins, complements, and immunoglobulins were normal or negative. Urine microscopy was normal and creatinine clearance was 47 ml/min. There was only minimal proteinuria. Renal biopsy showed inflammatory infiltrates with few eosinophils, periglomerular scarring, and peribular scarring. Immunofluorescence for IgG, IgA, IgM, and C3 were negative. The histological appearances were consistent with active chronic interstitial nephritis. He was given a
trial of prednisolone 60 mg daily, but there was no improvement in renal functions. At the time of reporting his colitis is quiescent while receiving prednisolone 3 mg daily and serum creatinine stable at 280 \( \mu \text{mol/l} \).

**Discussion**

Acute and chronic tubulointerstitial diseases are caused by a variety of agents.\(^1\) The clinical presentations depend on the type of the insult, the site and the extent of renal damage. As the histological changes are very non-specific with regard to the aetiology, the diagnosis is made on the basis of history. The chronic interstitial nephritis in our patients was probably caused by 5-ASA (mesalazine) as they did not have any other known aetiological factors and had normal renal functions before the treatment.

‘Analgesic nephropathy’ characterised by interstitial nephritis and papillary necrosis is the most common cause of drug related renal failure. Phenacetin, aspirin or salicylate compounds and non-steroidal anti-inflammatory drugs (NSAIDs) are known to cause this type of nephropathy.\(^2\)\(^-\)\(^4\) 5-ASA has structural similarities to salicylates and phenacetin. In experimental models 5-ASA was shown to be nephrotoxic.\(^5\)\(^-\)\(^7\) The mechanism of renal damage caused by 5-ASA may be similar to that of salicylates, probably by causing hypoxia of renal tissues either by uncoupling oxidative phosphorylation in renal mitochondria or by inhibiting the synthesis of renal prostaglandins.\(^4\)\(^-\)\(^8\) High renal concentrations of salicylates also make the kidneys susceptible to oxidative damage by reducing renal glutathione concentration by inhibition of the pentose phosphate shunt.\(^9\) Our first patient (case 1) had proteinuria in the nephrotic range. Similar cases, with histological changes mainly confined to interstitium, have been previously reported in association with other NSAIDs; it has been suggested that the nephrotic syndrome in these cases may be mediated by T-lymphocyte activation.\(^9\)\(^-\)\(^10\)

Despite the theoretical risk of microcrystallisation of sulfapyridine in the renal tubules, only few cases of renal toxicity have been reported with sulphasalazine use.\(^11\)\(^-\)\(^12\) In the small number of published reports, renal toxicity was seen as a part of a generalised hypersensitivity reaction to the drug. Since the introduction of 5-ASA, however, five cases of renal toxicity have been published.\(^13\)\(^-\)\(^17\) In addition to that, the Committee on Safety of Medicines in England and Wales has released information on nine possible cases of serious nephrotoxicity (four cases of interstitial nephritis, two nephrotic syndrome, and two renal failure) between February 1988 and December 1990 (including the cases reported here).\(^18\) Two of these patients had previous allergic reaction to sulphasalazine and one had renal dysfunction while receiving the drug. The two cases reported here were not receiving sulphasalazine before treatment with mesalazine. The significant delay between the onset of renal damage after treatment with mesalazine had started and the absence of other organ dysfunction suggest that the renal toxicity was not caused by a hypersensitivity reaction.

A number of studies have shown a significant correlation between the duration, the intensity, and the total dose of analgesics consumed and the degree of renal impairment.\(^2\)\(^-\)\(^3\)\(^-\)\(^8\) Our patients were receiving mesalazine 800 mg three times daily for 18–24 months when they were found to have renal impairment. 5-ASA is acetylated, independent of the acetylator status, to N-acetyl-5-ASA in the wall of ileum and colon.\(^19\) 5-ASA is absorbed in both the acetylated and non-acetylated form and once absorbed behaves similarly to other salicylates. Although it has been suggested that non-acetylated salicylates are less nephrotoxic,\(^20\)\(^-\)\(^21\) more recent studies have shown that both acetylated and non-acetylated forms of salicylate induce renal damage at similar doses.\(^6\)\(^-\)\(^7\)\(^-\)\(^22\) Under normal physiological conditions over 80% salicylate is inactivated in hepatic mitochondria to salicylate, which is not known to cause uncoupling of oxidative phosphorylation in renal mitochondria. In the kidney salicylates are filtered and secreted by proximal tubules. Passive reabsorption occurs throughout the nephron resulting in high cortical and medullary concentration compared with the plasma concentrations.\(^8\) Clearance of salicylate, possibly related to saturation of the secretory mechanism, shows a direct correlation with urine flow and negative correlation with the plasma concentration.

The absorption of 5-ASA and acetyl-5-ASA is predominantly from the small intestine.\(^23\)\(^-\)\(^24\) Plasma concentrations of 5-ASA and acetyl-5-ASA are higher in subjects with intact colon compared with those with ileostomy.\(^25\) The considerable individual variation in the absorption of these compounds makes it difficult to compare the published data on small group of subjects,\(^26\) yet detection of these compounds in subjects who had only enema preparations of 5-ASA or acetyl-5-ASA suggest that significant absorption may take place in the colon.\(^27\) The absorption from small bowel and colon depend on the pH, the
Mesalazine induced interstitial nephritis

transit time, the mode of delivery of the drug, and perhaps the integrity of the mucosa.25-31 Of these, the mode of delivery may be an important factor determining the peak plasma concentrations and thereby renal toxicity. On the basis of serum and 24 hour urinary excretion of 5-ASA and acetyl-5-ASA, it seems that maximum absorption is from plain 5-ASA preparations (almost 100%) followed by Asacol (20-30%), Pentasa (28-36%), and Dipentum (22-25%) in that order. The absorption from Asacol (coated with Eudragit S) seems to be lower than similar compounds like Claversal and Salofalk (coated with Eudragit L); this is related to the more proximal release of 5-ASA from these preparations.25 31 It is interesting to note that the serum concentrations of 5-ASA and acetyl-5-ASA from Pentasa, designed to deliver 5-ASA throughout the small bowel, is less than Asacol and similar compounds. This may result from incomplete release of 5-ASA from the granules25; or perhaps because the slow delivery does not overwhelm the acetylation capacity of the intestinal mucosa32 and assuming that acetyl-5-ASA is less well absorbed than 5-ASA. The absorption from olsalazine (Dipentum) seems to be similar to sulfasalazine making this compound, at least theoretically, less nephrotoxic.31 Our patients had total colitis. It is difficult to know whether this has predisposed them to the toxic effects of Asacol. It is possible that backwash ileitis and the change in pH may have led to the release of 5-ASA more proximally in the small bowel. Inflammation may also modify the mucosal acetylation and the absorption of 5-ASA and acetyl-5-ASA. The available data are insufficient, however, to find out if the absorption and the acetylation of 5-ASA compounds are related either to the extent or the severity of the disease.

Renal damage resulting from smaller doses of Asacol (400 mg three times daily) has also been reported suggesting that factors other than the amount of drug ingested may be involved. It has been suggested that prostaglandin inhibition enhances renal damage in the presence of hypovolaemia and salt depletion.4 With reference to this report, intravascular volume depletion resulting from diarrhoea may be a predisposing factor in patients with active inflammatory bowel disease. The longer term prognosis of our patients remains unclear. There has been no deterioration in renal functions since the drug was withdrawn, but the follow up of these patients has not been long enough to predict the future course. In patients with anergic nephropathy, about a third improve, a third remain stable, and a third deteriorate.33

In the case of analgesics, NSAIDs and 5-ASA, only a few patients develop renal damage. Patients with inflammatory bowel disease are more susceptible to damage because they will probably become dehydrated during exacerbation of their disease. As Asacol has been on the market longer than some other 5-ASA preparations, it is possible that nephrotoxicity may be noted with other preparations in the future. Sterile pyuria and low specific gravity are early features in salicylate induced renal damage. Proteinuria and hypertension are late, and suggest advanced disease. As there are definite advantages in using 5-ASA preparations over sulfasalazine in the treatment of inflammatory bowel disease, especially the higher doses in small bowel Crohn’s disease, it will be important to monitor renal functions and urine microscopy.

27 Campieri M, Lanfranchi GA, Boschi S, Brigolina C,


Mesalazine induced interstitial nephritis.

P J Thuluvath, M Ninkovic, J Calam and M Anderson

Gut 1994 35: 1493-1496
doi: 10.1136/gut.35.10.1493

Updated information and services can be found at:
http://gut.bmj.com/content/35/10/1493

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/